← Look up another trial

The Nitrite and Coronary Flow Study

NCT04354051 on ClinicalTrials.gov Phase 1/2 University of East Anglia (academic or other) Started 2018-07-01 Completed
Riskier than 20% of active trials
this trial: 11% 0% 36%

Model scores of the 29,894 trials active now.

Model score 11% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 17% of the time (106 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

How it ended

Completed on 2018-12-01, after 2018-07-01 start.

The score above never used this outcome: finished trial that started in 2015 or later: the model never saw it during training.

Termination over time, as the model saw it at the start

0% 22% 43% 65% 87% 0123456 yr completed 76% terminated 17%

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2018-12-01. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

What moved the score

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

The trial

Design

Phase
1/2 (typical: 2)
Number of arms
1 (typical: 2)
Allocation
not applicable (typical: randomized)
Design
single group (typical: parallel)
Primary purpose
treatment
Blinding
none
Has a data monitoring committee
No (typical: 56% yes)
Responsible party
sponsor
Collaborators
1 (typical: 0)
Keywords listed
0 (typical: 1)

Who can join

Minimum age
18
Maximum age
not given (typical: 71)
Sex
all
Accepts healthy volunteers
Yes (typical: 9% yes)

Sponsor's track record

Sponsor type
academic or other
Sponsor's past trials
17 (typical: 32)
Sponsor's past termination rate
0% (typical: 9.9%)
Trials the sponsor started in the prior 2 years
6 (typical: 19)

Drug's FDA history

Drugs with FDA adverse-event history
1
Drug has FAERS history
Yes (typical: 64% yes)
Drug's FAERS reports before start
166 (typical: 2148)
Drug's FAERS reports in the prior 12 months
30 (typical: 412.5)
Drug's FAERS reports marked serious
59.6% (typical: 85.6%)
Drug's FAERS reports with a death
15.1% (typical: 15.9%)

Disease area and drugs

Disease areas
cardiovascular
Drugs matched to FDA substances
nitrite

Typical values are among the trials active now. Sponsor and drug history are counted only up to this trial's start date.

Similar finished trials

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.